PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Integrated Care Pathway Cuts Early Polypharmacy But Not Agitation

integrated care pathwayagitationAlzheimer's diseasedementiapsychotropic polypharmacyantipsychoticsdeprescribinglong-term caremeasurement-based carerandomized controlled trialgeriatric psychiatry Geriatrics

Background Information

Standardizing care reduces polypharmacy in dementia agitation.

Agitation in Alzheimer's disease is common and challenging, with inconsistent adherence to treatment guidelines. The Integrated Care Pathway (ICP) reduced psychotropic polypharmacy in both inpatient and long-term-care home (LTCH) settings without impacting agitation levels. The study suggests that ICP can decrease medication burden without compromising efficacy, but findings were not significant at the 12-week endpoint. Standardizing care may reduce polypharmacy in dementia-related agitation.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Kumar S, Burhan AM, Colman S, Chu L, Davies S, Derkach P, Elmi S, Gerretsen P, Graff-Guerrero A, Greenway K, Hussain M, Ismail Z, Kim D, Krisman L, Ma C, Moghabghab R, Mulsant BH, Pollock BG, Rej S, Rostas A, Schoer N, Streiner DL, Van Bussel L, Rajji TK, StaN Study Group

Citation: Kumar S, Burhan AM, Colman S, et al. Standardizing care for agitation in Alzheimer's disease, results from a randomized controlled trial of an integrated care pathway versus usual care - the StaN trial. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026;22(7):e71610. doi:10.1002/alz.71610

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.